HK-listed Immunotech hits near 6-week high as China Resources Pharma buys stake

Reuters2021-07-21

** Shares of Immunotech Biopharm Ltd , which makes immune cell products for cancer treatment, rise as much as 8.9% to HK$20.80, their highest since June 11

** China Resources Pharmaceutical Group Ltd says unit has agreed to buy 10% of Immunotech from Yue Cheng International Capital, Hualida Development, Ren Xiaojuan and Bei Ni Ltd for HK$799.66 mln ($102.9 mln)

** Says unit has agreed to buy 51.46 mln existing shares of Beijing-based Immunotech at HK$15.54 each, further developing its business in cellular immunotherapy

** Shares of China Resources Pharmaceutical rise 1.8%

** The Hong Kong Hang Seng Commerce & Industry Index slips 0.8%, and the healthcare index falls 1%

** The Hang Seng China Enterprises Index slides 0.7%, and the benchmark index eases 0.5%

** By last close, Immunotech shares up 71.7% this year

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
7